(AGENPARL) - Roma, 18 Luglio 2024 - (AGENPARL) – gio 18 luglio 2024 7.00 AM CEST / 18-Jul-2024 / Hansa Biopharma AB (STO:HNSA)
Lund, Sweden, July 18, 2024, Hansa Biopharma today announced its first half and
second quarter 2024 financial results and business update.
Søren Tulstrup, President and CEO, Hansa Biopharma said: “For the third
consecutive quarter, Hansa Biopharma delivered solid IDEFIRIX[®] sales
performance driven by continued utilization of IDEFIRIX in key transplant
centers across all major European markets. Additionally, we continued to
progress key trials across the pipeline. Notably, we completed randomization of
all patients in ConfIdeS, our pivotal Phase 3 US trial in kidney
transplantation, and look forward to communicating data in the second half of
2025 with an expected Biologics License Application (BLA) submission to the US
Food and Drug Administration (FDA). Also, our Phase 3 trial in anti-glomerular
basement membrane (anti-GBM) disease and the European Post Authorization
Efficacy Study (PAES) in kidney transplant have both increased enrollment and
remain on track. Looking ahead, the Company has several important milestones in
the second half, including further analysis of data from the Phase 1 study of
HNSA-5487, the Company’s second-generation IgG cleaving enzyme designed to be re
-dosed.”
Financial Performance
The Company delivered strong financial performance for the third consecutive
quarter with total revenue of 54.2 MSEK. Of this, 47.1 MSEK is attributed to
IDEFIRIX sales. This excludes the impact of an approximate 20 MSEK provision
related to potential price adjustments from cumulative sales since the launch of
IDEFIRIX in Europe in 2020. After accounting for this provision, total IDEFIRIX
product sales were 27.2 MSEK.
Sales performance was primarily driven by continued expansion of IDEFIRIX in key
European markets. To date, the Company has secured reimbursement in 14 European
markets.
In Q2 2024, the Company completed a directed share issue, raising gross proceeds
of 372 MSEK (US $34.6M) primarily from high-quality international healthcare
specialist investors.
Pipeline Progress
Progress across the pipeline included the completed randomization in the
ConfIdeS pivotal Phase 3 US trial in kidney transplantation, further enrollment
in the European Post Approval Efficacy Study in kidney transplantation (70
percent) with expected completion by 2025, and continued enrollment (70 percent)
in the GOOD-IDES-12 Phase 3 trial in anti-GBM disease with data readout in 2025.
Financial Summary
[][]
MSEK, unless otherwise Q2 2024 Q2 2023 H1 2024 H1 2023
stated – unaudited
sales[1](Q2 product
sales
47.1 MSEK less
provision 19.9 MSEK =
27.2
MSEK)
SG&A expenses (88.2) (129.5) (179.5) (232.8)
R&D expenses (91.7) (114.7) (194.6) (207.5)
Loss from operations (187.4) (228.5) (346.8) (410.8)
Loss for the period (207.9) (251.2) (426.5) (456.6)
Net cash used in (189.2) (181.9) (378.3) (388.9)
operations
Cash and short-term 705.0 1,102.5 705.0 1,102.5
investments
EPS before and after (3.30) (4.79) (7.38) (8.71)
dilution (SEK)
Number of outstanding 67,814,241 52,443,962 67,814,241 52,443,962
shares
Weighted average 62,929,675 52,443,962 57,800,736 52,443,962
number of shares
before and
after dilution
end of the period
[1] Product sales in the second quarter 2024 totaled 47.1 MSEK. Sales were
offset by a provision totalling 19.9 MSEK for potential credits associated
with volume discounts and potential refunds. First half 2024 product sales
totaled 94.6 MSEK and were offset by the provision totaling 19.9 MSEK. Net of
the provision, first half product sales totaled 74.7 MSEK.
Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, July 18, 2024,
at 14:00 CET / 8:00 am EST.
The event will be hosted by Søren Tulstrup, President and CEO, Matthew Shaulis,
Chief Commercial Officer and US President, Evan Ballantyne, Chief Financial
Officer, and Hitto Kaufmann, Chief R&D Officer. The presentation will be held in
English.
Slides used in the presentation will be live on the company website during the
call under “Events & Presentations” and will also be made available online after
the call. Link to
presentation (https://investors.hansabiopharma.com/English/events-and
-presentations/presentations/default.aspx)
To participate in the telephone conference, please use the dial-in details
provided below:
Participant access code: 765135
The webcast will be available on https://hansabiopharma.eventcdn.net/events/half
-year-january-june-2024
For the full financial calendar and list of events in 2024 please visit
https://www.hansabiopharma.com/investors/calendar/
This is information that Hansa Biopharma AB is obliged to make public pursuant
to the Securities Markets Act.
For more information:
Evan Ballantyne, CFO
Stephanie Kenney, VP Global Corporate Affairs
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life altering
treatments for patients with rare immunological conditions. Hansa has developed
a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which
has been shown to enable kidney transplantation in highly sensitized patients.
Hansa has a rich and expanding research and development program, based on the
Company’s proprietary IgG-cleaving enzyme technology platform, to address
serious unmet medical needs in transplantation, autoimmune diseases, gene
therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations
in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at hansabiopharma.com.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/nJNByZ4eb4th4YLeqJULcjqbq29oHjdpkQe3quSxRpKaCxJWuJAPyiQZq4HwNXKuxterh3Zz34rqXD6rLWDwcfgJSRykz5nyVxNfpmFHXV9vC.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/nJNByZ4eb4th4YLeqJULcjqbq29oHjdpkQe3quSxRpKaCxJWuJAPyiQZq4HwNXKuxterh3Zz34rqXD6rLWDwcfgJSRykz5nyVxNfpmFHXV9vC.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Iran. De Corato (FdI): ragazza gettata dalla finestra dal padre, ecco Islam radicale come tratta donne
- Egitto e Libia, Sisi rafforza i rapporti con Tripoli senza abbandonare Haftar: energia e Mediterraneo al centro della strategia
- La Difensora civica Meyer al convegno delle Commissioni petizioni a Monaco
- Virgo Fidelis, patrona dell’Arma. Il presidente Senno alla cerimonia
- [Comune Palermo] Raddoppio Ponte Corleone. Dal 23 novembre varo nuovo impalcato lato Trapani
- Federazioni sportive, il Governo risponde ad Agenparl sui controlli ai lavoratori: «Il Dipartimento per lo Sport non esercita vigilanza sul CONI in materia». Richieste FOIA ritenute troppo ampie
- ZES, TURCO (M5S): FONDI SUD A TEMPO, MELONI NON RACCONTI FAVOLETTE
- Iran-USA, Araghchi rilancia il piano per Hormuz. Trump respinge le condizioni di Teheran
- Covid. Ciancitto (FdI): Italiani senza cura a causa di interessi Pd
- FBI, nuovo attacco informatico: nel mirino la banca dati criminale nazionale